SC
IKT icon

SummitTX Capital’s Inhibikase Therapeutics IKT Stock Holding History

SummitTX Capital’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.56M Buy
+1,524,536
New +$2.71M 0.08% 262

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SummitTX Capital's IKT Position: Q1 2026 in Review

SummitTX Capital opened a new position in Inhibikase Therapeutics (IKT) in Q1 2026: 1,524,536 shares worth $2.56M. The stake represents 0.08% of the portfolio and ranks #262 among its holdings.

104 funds tracked by Wall St. Rank hold IKT as of Q1 2026.

  • SummitTX Capital held 1,524,536 shares of Inhibikase Therapeutics worth $2.56M as of Q1 2026.
  • Inhibikase Therapeutics was a new SummitTX Capital position in Q1 2026.
  • Inhibikase Therapeutics made up 0.08% of SummitTX Capital's portfolio in Q1 2026, its #262 holding.
  • 104 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q1 2026.

Based on SummitTX Capital's 13F filing for Q1 2026, filed 15 May 2026.